ICYMI: AI drug finder and Euro funding for clinical robots

A week is a long time in artificial intelligence, so here’s a round-up of the AI Magazine articles that have been starting conversations around the world

European innovation fund backs Ganymed’s clinical robot work

Computer vision and robotics technology developer for orthopaedic clients Ganymed Robotics has extended its Series B funding with an additional €15 million, bringing the total Series B amount to €36 million. The Fund of the European Innovation Council, through its Accelerator Program, and Cap Horn invested €14 million. Bpifrance, the French national investment bank, extended a €1 million loan to finance market access work. The initial Series B close of €21 million, led by Cathay Health and joined by Crédit Mutuel Innovation, Kurma Partners and BNP Paribas Développement, was announced in July 2022.

Read the full story here.

Supernal collaborates with Microsoft to advance air mobility

Smart mobility service provider Supernal has announced a collaboration with Microsoft to advance autonomy, digital operations and cloud integration technologies for the aviation industry by running Advanced Air Mobility (AAM) on the Microsoft cloud platform. With Microsoft Azure, Supernal can leverage the flexibility and cloud computing power needed to run secure simulations at scale and accelerate its timeline to commercialisation. Formed by the Hyundai Motor Group in 2021, Supernal is developing a family of electric air vehicles and convening public and private stakeholders to responsibly shape the emerging AAM industry.

Read the full story here.

Employees fear robotics disruption following cyberattacks

The majority of employees are not ready to provide robots with full autonomy, a Kaspersky study has revealed, with the majority of respondents believing it could take days for businesses to recover in the event of a cyberattack. The research on the consequences of automation and increased use of robotics and other AI-based machines found most don’t believe production processes run by robots can be recovered immediately in case of a cyberattack or malfunction, with 78% believing full recovery will take a few days or longer.

Read the full story here.

AI to help find new drugs and trials for oncology patients

Cancer treatment technology provider Massive Bio is to launch an AI-powered drug-matching product designed to help oncologists identify more cancer treatment options for patients, including recently approved drugs and active clinical trials. The new drug-matching product will also help biotech and pharmaceutical companies better target which patients and physicians need the latest drugs, improving their go-to-market efficiency. Massive Bio plans to launch the product in the first half of 2023 with general availability achieved later this year.

Read the full story here.  

Machine learning tool joins the battle against “long COVID”

Long COVID, a condition in which patients experience chronic symptoms from the initial COVID-19 infection, has become a pandemic within the pandemic, and researchers are using machine learning to discover why some people develop debilitating long-lasting symptoms. A team of US researchers has developed a machine learning tool that analyses electronic health records (EHRs) to identify common symptoms and define subtypes of long COVID. The research, published in eBioMedicine, also found strong correlations between long COVID subtypes and pre-existing conditions like diabetes and hypertension.

Read the full story here.


Featured Articles

Google unveils Gemini: its largest AI model to date

After reportedly being delayed, Google launches its Gemini AI model, stating it is built from the ground up for multimodality - with seamless reasoning

Meta and IBM form ‘AI Alliance’ to promote open-source AI

Both tech companies have created an AI Alliance, along with more than 50 other organisations, to unite in support for open innovation and open-sourced AI

Google DeepMind launches deep learning tool: GNoME

GNoME highlights the potential of using AI to discover and develop new materials at scale and offers promise to develop future transformative technologies

Overseeing safe and responsible AI in 2024 with Dynatrace

Data & Analytics

Microsoft to invest £2.5 billion into global AI development


IBM & Boehringer Ingelheim partner to advance health GenAI

Machine Learning